| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 31 | 2017 | 390 | 5.350 |
Why?
|
| Vaccination | 31 | 2022 | 674 | 3.500 |
Why?
|
| Parents | 22 | 2017 | 309 | 3.220 |
Why?
|
| Humans | 215 | 2024 | 18430 | 3.170 |
Why?
|
| Physicians, Primary Care | 6 | 2022 | 74 | 3.150 |
Why?
|
| Vaccines | 16 | 2017 | 222 | 2.760 |
Why?
|
| Child, Preschool | 70 | 2024 | 1478 | 2.680 |
Why?
|
| Deductibles and Coinsurance | 7 | 2012 | 31 | 2.520 |
Why?
|
| Child | 82 | 2024 | 2571 | 2.510 |
Why?
|
| Influenza, Human | 17 | 2014 | 282 | 2.490 |
Why?
|
| Influenza Vaccines | 15 | 2012 | 290 | 2.460 |
Why?
|
| United States | 89 | 2024 | 4164 | 2.300 |
Why?
|
| Practice Patterns, Physicians' | 9 | 2019 | 350 | 2.280 |
Why?
|
| Infant | 69 | 2024 | 1245 | 2.180 |
Why?
|
| Electronic Mail | 3 | 2021 | 53 | 2.140 |
Why?
|
| Anti-Asthmatic Agents | 9 | 2017 | 85 | 2.120 |
Why?
|
| Male | 99 | 2024 | 10440 | 2.000 |
Why?
|
| Female | 110 | 2024 | 13136 | 1.990 |
Why?
|
| Health Maintenance Organizations | 34 | 2016 | 479 | 1.980 |
Why?
|
| Health Care Costs | 16 | 2013 | 251 | 1.970 |
Why?
|
| Cost-Benefit Analysis | 37 | 2017 | 270 | 1.940 |
Why?
|
| Medicaid | 15 | 2009 | 211 | 1.900 |
Why?
|
| Pediatrics | 14 | 2024 | 166 | 1.820 |
Why?
|
| Product Surveillance, Postmarketing | 10 | 2015 | 110 | 1.790 |
Why?
|
| Delivery of Health Care | 8 | 2022 | 444 | 1.790 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2022 | 116 | 1.630 |
Why?
|
| Pneumococcal Vaccines | 9 | 2009 | 80 | 1.620 |
Why?
|
| Attitude of Health Personnel | 9 | 2019 | 226 | 1.600 |
Why?
|
| Insurance, Health | 9 | 2013 | 217 | 1.570 |
Why?
|
| Immunization Programs | 13 | 2012 | 68 | 1.530 |
Why?
|
| Adult | 62 | 2021 | 7910 | 1.470 |
Why?
|
| Cross-Sectional Studies | 26 | 2021 | 1360 | 1.430 |
Why?
|
| Immunization | 9 | 2016 | 80 | 1.400 |
Why?
|
| Financing, Personal | 4 | 2013 | 24 | 1.390 |
Why?
|
| Patient Acceptance of Health Care | 8 | 2024 | 407 | 1.340 |
Why?
|
| Vaccines, Combined | 10 | 2012 | 91 | 1.330 |
Why?
|
| Adolescent | 50 | 2024 | 3798 | 1.240 |
Why?
|
| Decision Support Techniques | 13 | 2020 | 95 | 1.230 |
Why?
|
| Surveys and Questionnaires | 18 | 2024 | 1389 | 1.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 11 | 2016 | 392 | 1.140 |
Why?
|
| Physician-Patient Relations | 7 | 2024 | 197 | 1.100 |
Why?
|
| Office Visits | 8 | 2024 | 86 | 1.100 |
Why?
|
| Managed Care Programs | 11 | 2009 | 347 | 1.090 |
Why?
|
| Primary Health Care | 9 | 2024 | 848 | 1.080 |
Why?
|
| Middle Aged | 40 | 2021 | 8284 | 1.080 |
Why?
|
| Attitude to Health | 8 | 2015 | 177 | 1.070 |
Why?
|
| Cohort Studies | 35 | 2024 | 2672 | 1.070 |
Why?
|
| Health Services Research | 8 | 2017 | 264 | 1.030 |
Why?
|
| Health Services | 4 | 2011 | 117 | 1.020 |
Why?
|
| Physicians | 3 | 2022 | 141 | 1.020 |
Why?
|
| Guideline Adherence | 5 | 2012 | 162 | 1.000 |
Why?
|
| Medical Records Systems, Computerized | 5 | 2021 | 95 | 0.990 |
Why?
|
| Child Health Services | 10 | 2003 | 129 | 0.970 |
Why?
|
| Decision Making | 7 | 2016 | 204 | 0.960 |
Why?
|
| Retrospective Studies | 33 | 2021 | 2550 | 0.950 |
Why?
|
| Health Services Accessibility | 7 | 2010 | 320 | 0.950 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 249 | 0.940 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 6 | 2011 | 101 | 0.930 |
Why?
|
| Adrenergic beta-Agonists | 6 | 2016 | 33 | 0.930 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 6 | 2012 | 56 | 0.910 |
Why?
|
| Biomedical Research | 2 | 2017 | 93 | 0.910 |
Why?
|
| Data Collection | 9 | 2015 | 275 | 0.900 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2016 | 72 | 0.880 |
Why?
|
| Leukotriene Antagonists | 4 | 2016 | 12 | 0.870 |
Why?
|
| Electronic Health Records | 6 | 2021 | 747 | 0.870 |
Why?
|
| Chronic Disease | 9 | 2015 | 468 | 0.870 |
Why?
|
| Family Health | 3 | 2012 | 49 | 0.850 |
Why?
|
| Infant, Newborn | 31 | 2017 | 872 | 0.850 |
Why?
|
| Time Factors | 19 | 2021 | 1136 | 0.840 |
Why?
|
| Genetic Testing | 4 | 2017 | 89 | 0.840 |
Why?
|
| Otitis Media | 7 | 2011 | 21 | 0.840 |
Why?
|
| Allied Health Personnel | 1 | 2022 | 13 | 0.820 |
Why?
|
| Aged | 27 | 2022 | 6417 | 0.820 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2016 | 760 | 0.820 |
Why?
|
| Community Participation | 3 | 2011 | 33 | 0.810 |
Why?
|
| Hospitalization | 19 | 2024 | 847 | 0.800 |
Why?
|
| Antiviral Agents | 2 | 2012 | 95 | 0.790 |
Why?
|
| Breast Feeding | 8 | 2004 | 133 | 0.790 |
Why?
|
| California | 28 | 2024 | 2365 | 0.790 |
Why?
|
| Whooping Cough | 4 | 2007 | 75 | 0.790 |
Why?
|
| Practice Guidelines as Topic | 8 | 2016 | 333 | 0.790 |
Why?
|
| Drug Prescriptions | 4 | 2015 | 157 | 0.780 |
Why?
|
| Quality-Adjusted Life Years | 8 | 2012 | 41 | 0.770 |
Why?
|
| Hispanic Americans | 6 | 2017 | 428 | 0.760 |
Why?
|
| Multitasking Behavior | 1 | 2021 | 2 | 0.760 |
Why?
|
| Immunization Schedule | 10 | 2016 | 133 | 0.750 |
Why?
|
| Attention | 1 | 2021 | 10 | 0.750 |
Why?
|
| Workload | 1 | 2021 | 30 | 0.750 |
Why?
|
| Poverty | 4 | 2011 | 182 | 0.740 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 1037 | 0.730 |
Why?
|
| Drug Utilization | 5 | 2009 | 134 | 0.710 |
Why?
|
| Occupational Stress | 1 | 2019 | 3 | 0.700 |
Why?
|
| Health Policy | 10 | 2013 | 136 | 0.690 |
Why?
|
| Fever | 4 | 2016 | 60 | 0.690 |
Why?
|
| Ambulatory Care | 7 | 2014 | 266 | 0.680 |
Why?
|
| Models, Statistical | 5 | 2012 | 185 | 0.680 |
Why?
|
| Financing, Government | 4 | 2009 | 32 | 0.670 |
Why?
|
| Seizures | 3 | 2016 | 30 | 0.660 |
Why?
|
| Massachusetts | 11 | 2013 | 99 | 0.650 |
Why?
|
| Information Dissemination | 2 | 2018 | 57 | 0.650 |
Why?
|
| Length of Stay | 8 | 2004 | 183 | 0.640 |
Why?
|
| Datasets as Topic | 1 | 2018 | 17 | 0.640 |
Why?
|
| Health Benefit Plans, Employee | 2 | 2012 | 20 | 0.620 |
Why?
|
| Pneumococcal Infections | 6 | 2011 | 53 | 0.610 |
Why?
|
| Emergency Service, Hospital | 11 | 2024 | 382 | 0.600 |
Why?
|
| Mass Vaccination | 5 | 2012 | 22 | 0.600 |
Why?
|
| Chickenpox | 6 | 2008 | 38 | 0.600 |
Why?
|
| Value of Life | 4 | 2008 | 7 | 0.590 |
Why?
|
| Developing Countries | 3 | 2007 | 16 | 0.590 |
Why?
|
| Qualitative Research | 5 | 2022 | 272 | 0.590 |
Why?
|
| Herpes Zoster Vaccine | 2 | 2009 | 64 | 0.580 |
Why?
|
| Databases, Factual | 7 | 2015 | 327 | 0.580 |
Why?
|
| Socioeconomic Factors | 11 | 2013 | 673 | 0.580 |
Why?
|
| Multivariate Analysis | 14 | 2015 | 598 | 0.570 |
Why?
|
| Health Promotion | 4 | 2024 | 294 | 0.570 |
Why?
|
| Outcome Assessment (Health Care) | 8 | 2014 | 254 | 0.570 |
Why?
|
| Herpes Zoster | 2 | 2009 | 88 | 0.570 |
Why?
|
| Health Status | 6 | 2012 | 328 | 0.560 |
Why?
|
| Health Insurance Exchanges | 2 | 2013 | 5 | 0.550 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 58 | 0.540 |
Why?
|
| Quality Indicators, Health Care | 5 | 2017 | 197 | 0.530 |
Why?
|
| Treatment Outcome | 12 | 2015 | 1296 | 0.530 |
Why?
|
| Computer Simulation | 6 | 2014 | 85 | 0.520 |
Why?
|
| Patient Preference | 3 | 2020 | 45 | 0.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 50 | 0.520 |
Why?
|
| Bacterial Vaccines | 2 | 2009 | 17 | 0.520 |
Why?
|
| Risk | 14 | 2014 | 552 | 0.520 |
Why?
|
| Meningococcal Vaccines | 2 | 2007 | 46 | 0.510 |
Why?
|
| Reminder Systems | 4 | 2007 | 94 | 0.510 |
Why?
|
| Postnatal Care | 5 | 2004 | 22 | 0.500 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 146 | 0.500 |
Why?
|
| Streptococcal Infections | 6 | 2005 | 22 | 0.500 |
Why?
|
| Quality of Life | 7 | 2017 | 529 | 0.490 |
Why?
|
| Treatment Refusal | 1 | 2015 | 38 | 0.490 |
Why?
|
| Lung Diseases | 2 | 2011 | 43 | 0.480 |
Why?
|
| Income | 3 | 2011 | 98 | 0.480 |
Why?
|
| Database Management Systems | 2 | 2011 | 15 | 0.480 |
Why?
|
| Comparative Effectiveness Research | 2 | 2012 | 77 | 0.470 |
Why?
|
| Risk Factors | 21 | 2014 | 3449 | 0.470 |
Why?
|
| Patient Compliance | 3 | 2007 | 318 | 0.470 |
Why?
|
| Sentinel Surveillance | 1 | 2013 | 14 | 0.460 |
Why?
|
| Ethnic Groups | 7 | 2010 | 501 | 0.460 |
Why?
|
| Vaccines, Attenuated | 5 | 2014 | 47 | 0.450 |
Why?
|
| Prospective Studies | 13 | 2012 | 1314 | 0.450 |
Why?
|
| Young Adult | 14 | 2016 | 2518 | 0.450 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 5 | 2012 | 95 | 0.440 |
Why?
|
| Administration, Inhalation | 7 | 2015 | 37 | 0.440 |
Why?
|
| Cost Savings | 2 | 2011 | 25 | 0.440 |
Why?
|
| Health Care Surveys | 7 | 2011 | 247 | 0.430 |
Why?
|
| Oseltamivir | 1 | 2012 | 3 | 0.430 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 1997 | 12 | 0.430 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2000 | 24 | 0.430 |
Why?
|
| Cost of Illness | 7 | 2013 | 100 | 0.430 |
Why?
|
| Mothers | 2 | 2004 | 110 | 0.420 |
Why?
|
| Models, Theoretical | 4 | 2005 | 76 | 0.420 |
Why?
|
| Community-Institutional Relations | 3 | 2015 | 47 | 0.410 |
Why?
|
| Telephone | 6 | 2024 | 179 | 0.400 |
Why?
|
| Patient Readmission | 4 | 2004 | 162 | 0.400 |
Why?
|
| Insurance Benefits | 2 | 2011 | 15 | 0.390 |
Why?
|
| Community Health Centers | 5 | 2010 | 112 | 0.390 |
Why?
|
| For-Profit Insurance Plans | 1 | 2011 | 2 | 0.390 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 2003 | 0.390 |
Why?
|
| Sleep Wake Disorders | 1 | 2011 | 38 | 0.380 |
Why?
|
| Patient Satisfaction | 5 | 2017 | 232 | 0.380 |
Why?
|
| Glucocorticoids | 2 | 2009 | 21 | 0.380 |
Why?
|
| Risk Assessment | 11 | 2012 | 1143 | 0.380 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2010 | 6 | 0.380 |
Why?
|
| Health Expenditures | 2 | 2009 | 82 | 0.370 |
Why?
|
| Health Priorities | 3 | 2016 | 28 | 0.370 |
Why?
|
| Prepaid Health Plans | 1 | 2010 | 22 | 0.370 |
Why?
|
| Myocardial Infarction | 4 | 1997 | 249 | 0.370 |
Why?
|
| African Americans | 4 | 2015 | 490 | 0.360 |
Why?
|
| Preventive Health Services | 3 | 2010 | 166 | 0.360 |
Why?
|
| Medically Uninsured | 2 | 2007 | 61 | 0.360 |
Why?
|
| Logistic Models | 13 | 2015 | 962 | 0.360 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2010 | 7 | 0.350 |
Why?
|
| Process Assessment (Health Care) | 2 | 2015 | 28 | 0.350 |
Why?
|
| Infant, Premature | 4 | 2017 | 60 | 0.350 |
Why?
|
| Monitoring, Physiologic | 2 | 2015 | 41 | 0.350 |
Why?
|
| Haemophilus Vaccines | 2 | 2009 | 25 | 0.350 |
Why?
|
| United States Food and Drug Administration | 4 | 2015 | 36 | 0.350 |
Why?
|
| Chickenpox Vaccine | 7 | 2012 | 101 | 0.350 |
Why?
|
| Odds Ratio | 7 | 2016 | 701 | 0.340 |
Why?
|
| Vaccines, Conjugate | 4 | 2004 | 66 | 0.340 |
Why?
|
| Moraxella (Branhamella) catarrhalis | 1 | 2009 | 1 | 0.340 |
Why?
|
| Moraxellaceae Infections | 1 | 2009 | 1 | 0.340 |
Why?
|
| Pertussis Vaccine | 2 | 2007 | 17 | 0.340 |
Why?
|
| Otitis Media with Effusion | 1 | 2009 | 4 | 0.340 |
Why?
|
| Incidence | 10 | 2012 | 1314 | 0.340 |
Why?
|
| Age Factors | 6 | 2016 | 965 | 0.340 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 8 | 0.340 |
Why?
|
| Amoxicillin | 2 | 2008 | 3 | 0.340 |
Why?
|
| Quality of Health Care | 5 | 2010 | 347 | 0.340 |
Why?
|
| Administrative Personnel | 1 | 2009 | 6 | 0.330 |
Why?
|
| Family Characteristics | 1 | 2009 | 54 | 0.330 |
Why?
|
| Cardiovascular Diseases | 4 | 2012 | 630 | 0.330 |
Why?
|
| Pneumonia | 2 | 2007 | 56 | 0.320 |
Why?
|
| European Continental Ancestry Group | 3 | 2008 | 554 | 0.320 |
Why?
|
| Guillain-Barre Syndrome | 5 | 2014 | 19 | 0.320 |
Why?
|
| Treatment Failure | 1 | 2008 | 36 | 0.310 |
Why?
|
| Hospitals | 2 | 2010 | 80 | 0.310 |
Why?
|
| Steroids | 1 | 2008 | 15 | 0.310 |
Why?
|
| Research Support as Topic | 3 | 2017 | 23 | 0.310 |
Why?
|
| Self Care | 1 | 2009 | 175 | 0.310 |
Why?
|
| Models, Psychological | 1 | 2007 | 25 | 0.300 |
Why?
|
| Costs and Cost Analysis | 7 | 2008 | 89 | 0.300 |
Why?
|
| Echoencephalography | 1 | 2007 | 1 | 0.300 |
Why?
|
| Internet | 3 | 2015 | 243 | 0.300 |
Why?
|
| Attitude | 1 | 2008 | 33 | 0.300 |
Why?
|
| Anemia, Sickle Cell | 1 | 2007 | 9 | 0.300 |
Why?
|
| Erythrocyte Transfusion | 1 | 2007 | 9 | 0.300 |
Why?
|
| Patients | 1 | 2008 | 38 | 0.300 |
Why?
|
| State Government | 1 | 2007 | 14 | 0.300 |
Why?
|
| Patient Discharge | 5 | 2017 | 153 | 0.300 |
Why?
|
| Communication | 2 | 2016 | 202 | 0.300 |
Why?
|
| Preventive Medicine | 2 | 2007 | 25 | 0.300 |
Why?
|
| Jaundice, Neonatal | 2 | 2004 | 17 | 0.290 |
Why?
|
| Models, Economic | 3 | 2011 | 22 | 0.290 |
Why?
|
| Cystic Fibrosis | 2 | 1999 | 8 | 0.290 |
Why?
|
| Family Practice | 2 | 2004 | 53 | 0.290 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 6 | 2012 | 67 | 0.290 |
Why?
|
| Bordetella pertussis | 1 | 2007 | 6 | 0.290 |
Why?
|
| Postal Service | 3 | 2022 | 83 | 0.290 |
Why?
|
| African Continental Ancestry Group | 1 | 2008 | 166 | 0.290 |
Why?
|
| Laboratories, Hospital | 2 | 2015 | 4 | 0.290 |
Why?
|
| Choice Behavior | 3 | 2014 | 48 | 0.290 |
Why?
|
| Intention | 2 | 2022 | 28 | 0.290 |
Why?
|
| Self Report | 2 | 2013 | 256 | 0.280 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2017 | 567 | 0.280 |
Why?
|
| Serologic Tests | 2 | 1998 | 6 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2011 | 342 | 0.280 |
Why?
|
| Clinical Competence | 2 | 2004 | 108 | 0.280 |
Why?
|
| Outcome and Process Assessment (Health Care) | 5 | 2016 | 110 | 0.280 |
Why?
|
| Respiratory Tract Infections | 2 | 2004 | 54 | 0.270 |
Why?
|
| Peptic Ulcer | 2 | 2003 | 14 | 0.270 |
Why?
|
| Acute Disease | 5 | 2009 | 144 | 0.270 |
Why?
|
| Helicobacter Infections | 2 | 2003 | 22 | 0.270 |
Why?
|
| Helicobacter pylori | 2 | 2003 | 24 | 0.270 |
Why?
|
| Mass Media | 1 | 2006 | 17 | 0.270 |
Why?
|
| Neonatal Screening | 2 | 2002 | 13 | 0.270 |
Why?
|
| Streptococcus agalactiae | 3 | 2005 | 8 | 0.270 |
Why?
|
| Leadership | 2 | 2024 | 45 | 0.260 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2004 | 25 | 0.260 |
Why?
|
| Diphtheria-Tetanus Vaccine | 1 | 2005 | 3 | 0.260 |
Why?
|
| Research Design | 6 | 2016 | 402 | 0.260 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 1269 | 0.260 |
Why?
|
| Research Personnel | 1 | 2015 | 30 | 0.250 |
Why?
|
| Insurance Claim Review | 4 | 2016 | 70 | 0.250 |
Why?
|
| New England | 3 | 2011 | 13 | 0.250 |
Why?
|
| Intussusception | 3 | 2014 | 16 | 0.250 |
Why?
|
| Sickness Impact Profile | 1 | 2005 | 28 | 0.250 |
Why?
|
| Sensitivity and Specificity | 8 | 2006 | 321 | 0.250 |
Why?
|
| International Classification of Diseases | 3 | 2013 | 87 | 0.250 |
Why?
|
| Severity of Illness Index | 7 | 2010 | 476 | 0.250 |
Why?
|
| Diabetes Mellitus | 4 | 2015 | 530 | 0.250 |
Why?
|
| Decision Trees | 7 | 2007 | 20 | 0.240 |
Why?
|
| Rotavirus Vaccines | 3 | 2014 | 50 | 0.240 |
Why?
|
| Politics | 1 | 2024 | 13 | 0.240 |
Why?
|
| Pregnancy | 9 | 2017 | 1516 | 0.240 |
Why?
|
| Interviews as Topic | 6 | 2014 | 327 | 0.240 |
Why?
|
| Stroke | 1 | 2007 | 311 | 0.240 |
Why?
|
| Pharyngitis | 3 | 1990 | 11 | 0.240 |
Why?
|
| Metapneumovirus | 1 | 2004 | 1 | 0.240 |
Why?
|
| Paramyxoviridae Infections | 1 | 2004 | 2 | 0.240 |
Why?
|
| Cultural Diversity | 1 | 2004 | 17 | 0.240 |
Why?
|
| Markov Chains | 4 | 2012 | 24 | 0.240 |
Why?
|
| Immunization, Secondary | 4 | 2015 | 64 | 0.240 |
Why?
|
| Child Health | 1 | 2024 | 34 | 0.240 |
Why?
|
| Poliovirus Vaccine, Inactivated | 2 | 2001 | 21 | 0.240 |
Why?
|
| Boston | 3 | 2011 | 37 | 0.240 |
Why?
|
| State Health Plans | 4 | 2013 | 44 | 0.240 |
Why?
|
| Drug Administration Schedule | 3 | 2009 | 100 | 0.230 |
Why?
|
| Counseling | 3 | 2006 | 197 | 0.230 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 195 | 0.230 |
Why?
|
| Health Systems Plans | 1 | 2013 | 4 | 0.230 |
Why?
|
| Medical Record Linkage | 3 | 2014 | 44 | 0.230 |
Why?
|
| Vital Signs | 1 | 2013 | 14 | 0.230 |
Why?
|
| Early Medical Intervention | 1 | 2013 | 10 | 0.230 |
Why?
|
| Public Health Practice | 1 | 2003 | 14 | 0.230 |
Why?
|
| Weaning | 1 | 2003 | 6 | 0.230 |
Why?
|
| Anti-Ulcer Agents | 1 | 2003 | 5 | 0.220 |
Why?
|
| Appointments and Schedules | 1 | 2003 | 34 | 0.220 |
Why?
|
| Herpesvirus 3, Human | 2 | 2008 | 49 | 0.220 |
Why?
|
| Patient-Centered Care | 3 | 2015 | 228 | 0.220 |
Why?
|
| Histamine H2 Antagonists | 1 | 2003 | 13 | 0.220 |
Why?
|
| Mumps Vaccine | 4 | 1998 | 8 | 0.220 |
Why?
|
| Rubella Vaccine | 4 | 1998 | 9 | 0.220 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 2 | 2003 | 3 | 0.220 |
Why?
|
| Measles Vaccine | 4 | 1998 | 21 | 0.220 |
Why?
|
| Case-Control Studies | 6 | 2015 | 1173 | 0.220 |
Why?
|
| Consumer Behavior | 3 | 2013 | 30 | 0.220 |
Why?
|
| Confidence Intervals | 3 | 2011 | 253 | 0.220 |
Why?
|
| Seizures, Febrile | 3 | 2014 | 47 | 0.220 |
Why?
|
| Hearing Disorders | 1 | 2002 | 3 | 0.220 |
Why?
|
| Infant, Premature, Diseases | 2 | 2000 | 16 | 0.220 |
Why?
|
| Deafness | 1 | 2002 | 5 | 0.210 |
Why?
|
| Registries | 3 | 2020 | 490 | 0.210 |
Why?
|
| Organizations | 1 | 2022 | 10 | 0.210 |
Why?
|
| Internship and Residency | 3 | 1992 | 50 | 0.210 |
Why?
|
| Electronics | 1 | 2022 | 4 | 0.210 |
Why?
|
| Genetic Counseling | 1 | 2012 | 35 | 0.210 |
Why?
|
| Cluster Analysis | 3 | 2015 | 96 | 0.210 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2005 | 30 | 0.200 |
Why?
|
| Continental Population Groups | 3 | 2017 | 315 | 0.200 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2017 | 41 | 0.200 |
Why?
|
| Quality Improvement | 3 | 2020 | 207 | 0.200 |
Why?
|
| Fever of Unknown Origin | 2 | 1992 | 3 | 0.200 |
Why?
|
| Cause of Death | 1 | 2012 | 185 | 0.200 |
Why?
|
| Case Management | 1 | 2011 | 37 | 0.200 |
Why?
|
| House Calls | 1 | 2001 | 13 | 0.200 |
Why?
|
| Patient Care Planning | 2 | 1999 | 51 | 0.200 |
Why?
|
| Life Style | 1 | 2013 | 342 | 0.200 |
Why?
|
| Health Literacy | 2 | 2013 | 40 | 0.190 |
Why?
|
| Pandemics | 2 | 2014 | 292 | 0.190 |
Why?
|
| Telemedicine | 1 | 2024 | 184 | 0.190 |
Why?
|
| Home Care Services | 2 | 2002 | 23 | 0.190 |
Why?
|
| Cooperative Behavior | 3 | 2017 | 102 | 0.190 |
Why?
|
| Blood Pressure | 1 | 2012 | 310 | 0.190 |
Why?
|
| Sex Factors | 2 | 2021 | 661 | 0.190 |
Why?
|
| Ethical Relativism | 1 | 2020 | 1 | 0.190 |
Why?
|
| Family | 4 | 2013 | 120 | 0.190 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2016 | 7 | 0.180 |
Why?
|
| Quality Assurance, Health Care | 3 | 2010 | 188 | 0.180 |
Why?
|
| Streptococcus pneumoniae | 1 | 2000 | 25 | 0.180 |
Why?
|
| Health Education | 2 | 2006 | 115 | 0.180 |
Why?
|
| Reimbursement Mechanisms | 2 | 2010 | 20 | 0.180 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 365 | 0.180 |
Why?
|
| Hyperlipidemias | 2 | 2015 | 58 | 0.170 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1999 | 8 | 0.170 |
Why?
|
| Thrombolytic Therapy | 2 | 1997 | 21 | 0.170 |
Why?
|
| Physicians, Family | 2 | 2017 | 47 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 1 | 1999 | 21 | 0.170 |
Why?
|
| Program Evaluation | 5 | 2012 | 244 | 0.170 |
Why?
|
| Cancer Survivors | 1 | 2020 | 89 | 0.170 |
Why?
|
| Population Surveillance | 2 | 2012 | 271 | 0.170 |
Why?
|
| Exercise | 1 | 2013 | 495 | 0.160 |
Why?
|
| Perinatal Care | 1 | 1998 | 13 | 0.160 |
Why?
|
| Ownership | 1 | 2018 | 15 | 0.160 |
Why?
|
| Insurance Coverage | 2 | 2010 | 136 | 0.160 |
Why?
|
| Access to Information | 1 | 2018 | 13 | 0.160 |
Why?
|
| Confidentiality | 1 | 2018 | 30 | 0.160 |
Why?
|
| Emergency Medical Services | 2 | 1998 | 47 | 0.160 |
Why?
|
| Neuralgia, Postherpetic | 2 | 2009 | 15 | 0.160 |
Why?
|
| Albuterol | 2 | 2016 | 7 | 0.150 |
Why?
|
| Healthcare Disparities | 2 | 2011 | 211 | 0.150 |
Why?
|
| Focus Groups | 2 | 2016 | 154 | 0.150 |
Why?
|
| Regression Analysis | 5 | 2007 | 319 | 0.150 |
Why?
|
| Patient Safety | 2 | 2015 | 41 | 0.150 |
Why?
|
| Ambulatory Care Facilities | 5 | 2009 | 77 | 0.150 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 160 | 0.150 |
Why?
|
| Prenatal Care | 2 | 1999 | 134 | 0.150 |
Why?
|
| Probability | 4 | 2008 | 86 | 0.150 |
Why?
|
| Viral Vaccines | 2 | 1994 | 15 | 0.150 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2009 | 22 | 0.150 |
Why?
|
| Oncologists | 1 | 2017 | 7 | 0.140 |
Why?
|
| Value-Based Purchasing | 1 | 2017 | 3 | 0.140 |
Why?
|
| Statistics as Topic | 2 | 2015 | 66 | 0.140 |
Why?
|
| Chlorofluorocarbons | 1 | 2016 | 2 | 0.140 |
Why?
|
| Health Services Needs and Demand | 4 | 2013 | 109 | 0.140 |
Why?
|
| Vulnerable Populations | 2 | 2009 | 47 | 0.140 |
Why?
|
| Cost Sharing | 1 | 2016 | 40 | 0.140 |
Why?
|
| Parent-Child Relations | 1 | 2017 | 55 | 0.140 |
Why?
|
| Multigene Family | 1 | 2016 | 7 | 0.140 |
Why?
|
| Drug Costs | 3 | 2009 | 40 | 0.140 |
Why?
|
| Injections | 2 | 2010 | 5 | 0.140 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 34 | 0.130 |
Why?
|
| Hepatitis B Vaccines | 2 | 2006 | 46 | 0.130 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2007 | 5 | 0.130 |
Why?
|
| Thimerosal | 2 | 2007 | 5 | 0.130 |
Why?
|
| Private Sector | 2 | 2007 | 16 | 0.130 |
Why?
|
| Absenteeism | 2 | 2000 | 27 | 0.130 |
Why?
|
| Validation Studies as Topic | 2 | 2012 | 11 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2020 | 120 | 0.130 |
Why?
|
| Drug Labeling | 1 | 2015 | 15 | 0.130 |
Why?
|
| Motivation | 2 | 2012 | 137 | 0.130 |
Why?
|
| Poisson Distribution | 4 | 2015 | 94 | 0.130 |
Why?
|
| Topography, Medical | 1 | 2015 | 5 | 0.130 |
Why?
|
| Premature Birth | 1 | 2017 | 138 | 0.130 |
Why?
|
| Models, Immunological | 1 | 2014 | 3 | 0.130 |
Why?
|
| Seasons | 3 | 2012 | 105 | 0.120 |
Why?
|
| Utilization Review | 1 | 2015 | 56 | 0.120 |
Why?
|
| Health Personnel | 1 | 2016 | 126 | 0.120 |
Why?
|
| Mental Disorders | 2 | 2012 | 295 | 0.120 |
Why?
|
| Genetic Carrier Screening | 1 | 1994 | 22 | 0.120 |
Why?
|
| Data Accuracy | 1 | 2015 | 27 | 0.120 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2015 | 43 | 0.120 |
Why?
|
| Bacteremia | 3 | 2004 | 15 | 0.120 |
Why?
|
| Rhinitis, Allergic | 1 | 2014 | 3 | 0.120 |
Why?
|
| Models, Econometric | 3 | 2005 | 11 | 0.120 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2011 | 19 | 0.120 |
Why?
|
| Vaccines, Inactivated | 3 | 2012 | 70 | 0.120 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 18 | 0.120 |
Why?
|
| Hematuria | 2 | 1991 | 7 | 0.120 |
Why?
|
| Obstetrics | 2 | 2004 | 23 | 0.120 |
Why?
|
| Community Networks | 1 | 2014 | 28 | 0.120 |
Why?
|
| Suicide, Attempted | 1 | 2015 | 98 | 0.120 |
Why?
|
| Consumer Health Information | 2 | 2013 | 14 | 0.110 |
Why?
|
| Age Distribution | 4 | 2010 | 261 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 2 | 2012 | 151 | 0.110 |
Why?
|
| Postpartum Period | 2 | 2005 | 93 | 0.110 |
Why?
|
| Overweight | 3 | 2013 | 276 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 2013 | 22 | 0.110 |
Why?
|
| Fee-for-Service Plans | 1 | 2013 | 28 | 0.110 |
Why?
|
| Medicare | 2 | 2013 | 214 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2011 | 399 | 0.110 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2013 | 22 | 0.110 |
Why?
|
| Medicare Part C | 1 | 2013 | 22 | 0.110 |
Why?
|
| Coronary Artery Bypass | 1 | 2013 | 26 | 0.110 |
Why?
|
| Sepsis | 2 | 2011 | 71 | 0.110 |
Why?
|
| Competitive Medical Plans | 1 | 2013 | 1 | 0.110 |
Why?
|
| Mental Health Services | 1 | 2015 | 161 | 0.110 |
Why?
|
| Adolescent Health Services | 1 | 1993 | 43 | 0.110 |
Why?
|
| Sex Distribution | 3 | 2010 | 198 | 0.110 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 743 | 0.110 |
Why?
|
| Educational Status | 3 | 2002 | 205 | 0.110 |
Why?
|
| Clinical Protocols | 2 | 2016 | 45 | 0.110 |
Why?
|
| Infant Care | 2 | 2002 | 6 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 36 | 0.100 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2012 | 5 | 0.100 |
Why?
|
| Diabetic Nephropathies | 1 | 2012 | 28 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 4 | 2000 | 142 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2011 | 13 | 0.100 |
Why?
|
| Professional-Family Relations | 2 | 2008 | 50 | 0.100 |
Why?
|
| Observation | 1 | 2011 | 25 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2015 | 267 | 0.100 |
Why?
|
| Sleep | 1 | 1992 | 57 | 0.100 |
Why?
|
| Program Development | 1 | 2012 | 81 | 0.100 |
Why?
|
| Middle Ear Ventilation | 2 | 2009 | 5 | 0.100 |
Why?
|
| Health Planning | 1 | 2011 | 17 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 182 | 0.100 |
Why?
|
| Health Plan Implementation | 1 | 2011 | 41 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2012 | 237 | 0.090 |
Why?
|
| Information Seeking Behavior | 1 | 2010 | 11 | 0.090 |
Why?
|
| Sleep Deprivation | 1 | 1990 | 4 | 0.090 |
Why?
|
| Child Welfare | 1 | 2010 | 40 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2011 | 53 | 0.090 |
Why?
|
| Health Care Reform | 2 | 2015 | 33 | 0.090 |
Why?
|
| Depression | 1 | 2015 | 518 | 0.090 |
Why?
|
| Ureter | 1 | 2010 | 2 | 0.090 |
Why?
|
| Urologic Surgical Procedures | 1 | 2010 | 7 | 0.090 |
Why?
|
| Mental Health | 1 | 2011 | 168 | 0.090 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2010 | 15 | 0.090 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2000 | 3 | 0.090 |
Why?
|
| Health Surveys | 1 | 2011 | 269 | 0.090 |
Why?
|
| Specialization | 1 | 1989 | 26 | 0.090 |
Why?
|
| Reward | 1 | 2009 | 7 | 0.090 |
Why?
|
| Students, Medical | 1 | 1989 | 17 | 0.090 |
Why?
|
| Economics | 1 | 2009 | 1 | 0.080 |
Why?
|
| Mass Screening | 2 | 2007 | 690 | 0.080 |
Why?
|
| Prescription Fees | 1 | 2009 | 4 | 0.080 |
Why?
|
| Demography | 2 | 2000 | 108 | 0.080 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1988 | 2 | 0.080 |
Why?
|
| Urinary Tract | 1 | 1988 | 2 | 0.080 |
Why?
|
| Recurrence | 2 | 2008 | 187 | 0.080 |
Why?
|
| Physicians' Offices | 1 | 2008 | 2 | 0.080 |
Why?
|
| Medication Errors | 1 | 2007 | 7 | 0.080 |
Why?
|
| Nursing Methodology Research | 1 | 2007 | 8 | 0.080 |
Why?
|
| Health Behavior | 1 | 2010 | 374 | 0.080 |
Why?
|
| Self Administration | 1 | 2007 | 12 | 0.080 |
Why?
|
| Pharmacies | 1 | 2008 | 10 | 0.080 |
Why?
|
| Information Systems | 2 | 1998 | 23 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 39 | 0.080 |
Why?
|
| Causality | 1 | 2007 | 43 | 0.080 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 11 | 0.080 |
Why?
|
| Intelligence | 1 | 2007 | 9 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 131 | 0.080 |
Why?
|
| Iron Chelating Agents | 1 | 2007 | 1 | 0.080 |
Why?
|
| Cerebrovascular Circulation | 1 | 2007 | 2 | 0.080 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 5 | 0.080 |
Why?
|
| Public Sector | 1 | 2007 | 9 | 0.070 |
Why?
|
| Likelihood Functions | 1 | 2007 | 48 | 0.070 |
Why?
|
| Social Problems | 1 | 2007 | 7 | 0.070 |
Why?
|
| Meningitis | 2 | 2009 | 4 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2007 | 33 | 0.070 |
Why?
|
| Developmental Disabilities | 2 | 2007 | 53 | 0.070 |
Why?
|
| Tracheotomy | 1 | 2007 | 2 | 0.070 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2007 | 2 | 0.070 |
Why?
|
| Child Development | 1 | 2007 | 52 | 0.070 |
Why?
|
| Spinal Fusion | 1 | 2007 | 5 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2007 | 16 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2005 | 46 | 0.070 |
Why?
|
| Checklist | 1 | 2016 | 15 | 0.070 |
Why?
|
| Meningitis, Pneumococcal | 2 | 2004 | 3 | 0.070 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2004 | 14 | 0.070 |
Why?
|
| Neoplasms | 1 | 2011 | 457 | 0.070 |
Why?
|
| Hospitals, Pediatric | 1 | 2007 | 80 | 0.070 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2016 | 24 | 0.070 |
Why?
|
| Prevalence | 3 | 2006 | 911 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2006 | 43 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2007 | 180 | 0.070 |
Why?
|
| Career Mobility | 1 | 2015 | 6 | 0.060 |
Why?
|
| Streptococcal Vaccines | 1 | 2005 | 1 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 25 | 0.060 |
Why?
|
| Disease Transmission, Infectious | 1 | 2005 | 13 | 0.060 |
Why?
|
| Anaphylaxis | 1 | 2005 | 15 | 0.060 |
Why?
|
| Societies, Scientific | 1 | 2015 | 3 | 0.060 |
Why?
|
| Advisory Committees | 2 | 2003 | 112 | 0.060 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 2 | 2011 | 33 | 0.060 |
Why?
|
| Streptococcus pyogenes | 3 | 1990 | 6 | 0.060 |
Why?
|
| Disease Management | 2 | 2007 | 143 | 0.060 |
Why?
|
| Diffusion of Innovation | 1 | 2024 | 44 | 0.060 |
Why?
|
| Dehydration | 1 | 2004 | 2 | 0.060 |
Why?
|
| Ohio | 1 | 2004 | 23 | 0.060 |
Why?
|
| Nurse Midwives | 1 | 2004 | 2 | 0.060 |
Why?
|
| Evidence-Based Practice | 1 | 2024 | 56 | 0.060 |
Why?
|
| Infection | 1 | 2004 | 17 | 0.060 |
Why?
|
| Nurse Practitioners | 1 | 2004 | 20 | 0.060 |
Why?
|
| Patient Admission | 3 | 2001 | 76 | 0.060 |
Why?
|
| Infant Formula | 1 | 2004 | 11 | 0.060 |
Why?
|
| Time | 1 | 2004 | 20 | 0.060 |
Why?
|
| Feeding and Eating Disorders | 1 | 2004 | 17 | 0.060 |
Why?
|
| Private Practice | 1 | 2003 | 15 | 0.060 |
Why?
|
| Linear Models | 1 | 2004 | 243 | 0.060 |
Why?
|
| Uncompensated Care | 1 | 2003 | 5 | 0.060 |
Why?
|
| Hypertension | 2 | 2015 | 524 | 0.060 |
Why?
|
| Nurse-Patient Relations | 1 | 2003 | 8 | 0.060 |
Why?
|
| Smallpox | 1 | 2003 | 4 | 0.060 |
Why?
|
| Smallpox Vaccine | 1 | 2003 | 6 | 0.060 |
Why?
|
| Personnel, Hospital | 1 | 2003 | 9 | 0.060 |
Why?
|
| Education | 1 | 2003 | 17 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 51 | 0.060 |
Why?
|
| Maternal Age | 1 | 2003 | 80 | 0.060 |
Why?
|
| Depression, Postpartum | 1 | 2003 | 18 | 0.050 |
Why?
|
| Expert Testimony | 1 | 2002 | 4 | 0.050 |
Why?
|
| Forecasting | 2 | 2005 | 80 | 0.050 |
Why?
|
| Disabled Persons | 1 | 2003 | 41 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 119 | 0.050 |
Why?
|
| Employment | 1 | 2003 | 48 | 0.050 |
Why?
|
| False Negative Reactions | 1 | 2002 | 12 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2002 | 26 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2002 | 7 | 0.050 |
Why?
|
| United States Dept. of Health and Human Services | 2 | 2012 | 7 | 0.050 |
Why?
|
| Chlamydia Infections | 1 | 2002 | 27 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2002 | 53 | 0.050 |
Why?
|
| Motor Activity | 1 | 2013 | 215 | 0.050 |
Why?
|
| Obstetric Labor Complications | 2 | 1999 | 14 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 1992 | 22 | 0.050 |
Why?
|
| Social Support | 1 | 2003 | 214 | 0.050 |
Why?
|
| Minority Groups | 1 | 2002 | 105 | 0.050 |
Why?
|
| Immunity | 1 | 2001 | 6 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2007 | 150 | 0.050 |
Why?
|
| Dyspepsia | 1 | 2001 | 5 | 0.050 |
Why?
|
| Insurance Carriers | 1 | 2000 | 6 | 0.050 |
Why?
|
| Weight Loss | 1 | 2013 | 321 | 0.050 |
Why?
|
| Morbidity | 2 | 1998 | 62 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 112 | 0.050 |
Why?
|
| Direct Service Costs | 1 | 2000 | 10 | 0.040 |
Why?
|
| Education, Medical | 2 | 1990 | 15 | 0.040 |
Why?
|
| Orthomyxoviridae | 1 | 2000 | 5 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 2000 | 27 | 0.040 |
Why?
|
| Palivizumab | 1 | 1999 | 2 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1999 | 12 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 1999 | 26 | 0.040 |
Why?
|
| Hospital Costs | 1 | 1999 | 41 | 0.040 |
Why?
|
| Gestational Age | 1 | 1999 | 119 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 1998 | 8 | 0.040 |
Why?
|
| Sampling Studies | 3 | 2006 | 55 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2013 | 86 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1998 | 14 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 1998 | 20 | 0.040 |
Why?
|
| Pharynx | 2 | 1988 | 3 | 0.040 |
Why?
|
| Medical History Taking | 1 | 1998 | 37 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 1997 | 9 | 0.040 |
Why?
|
| Laundering | 1 | 1997 | 2 | 0.040 |
Why?
|
| Bedding and Linens | 1 | 1997 | 4 | 0.040 |
Why?
|
| Lead Poisoning | 1 | 1997 | 3 | 0.040 |
Why?
|
| Writing | 1 | 1997 | 12 | 0.040 |
Why?
|
| Medication Reconciliation | 1 | 2017 | 5 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 1998 | 159 | 0.040 |
Why?
|
| Conflict of Interest | 1 | 2017 | 5 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 1998 | 214 | 0.040 |
Why?
|
| Soil | 1 | 2016 | 2 | 0.040 |
Why?
|
| Random Allocation | 1 | 1996 | 41 | 0.040 |
Why?
|
| Social Class | 1 | 1997 | 125 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2017 | 32 | 0.040 |
Why?
|
| Cardiology | 1 | 2017 | 30 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 1996 | 43 | 0.030 |
Why?
|
| Survival Analysis | 1 | 1996 | 226 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 12 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1996 | 133 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 22 | 0.030 |
Why?
|
| Pregnancy, High-Risk | 1 | 1994 | 4 | 0.030 |
Why?
|
| Cost Control | 1 | 1994 | 25 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 1994 | 18 | 0.030 |
Why?
|
| Suburban Population | 1 | 1994 | 3 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 167 | 0.030 |
Why?
|
| Pamphlets | 1 | 1994 | 8 | 0.030 |
Why?
|
| Abortion, Induced | 1 | 1994 | 17 | 0.030 |
Why?
|
| Drug Combinations | 1 | 1994 | 43 | 0.030 |
Why?
|
| Cost Allocation | 1 | 1994 | 2 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 1994 | 6 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2015 | 127 | 0.030 |
Why?
|
| Acyclovir | 1 | 1994 | 5 | 0.030 |
Why?
|
| Capitation Fee | 1 | 2013 | 12 | 0.030 |
Why?
|
| Geography | 1 | 2013 | 41 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2013 | 31 | 0.030 |
Why?
|
| Propensity Score | 1 | 2013 | 94 | 0.030 |
Why?
|
| Comprehension | 1 | 2013 | 16 | 0.030 |
Why?
|
| Epidemiologic Methods | 2 | 2005 | 87 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2015 | 346 | 0.030 |
Why?
|
| Disease Progression | 1 | 2013 | 271 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 1992 | 2 | 0.030 |
Why?
|
| Urinalysis | 1 | 1992 | 9 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 1992 | 10 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2013 | 51 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 288 | 0.030 |
Why?
|
| Hepatitis A Vaccines | 1 | 2012 | 14 | 0.030 |
Why?
|
| Public Health | 1 | 2012 | 82 | 0.030 |
Why?
|
| Bell Palsy | 1 | 2011 | 17 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2011 | 4 | 0.020 |
Why?
|
| Blindness | 1 | 2011 | 5 | 0.020 |
Why?
|
| Psychometrics | 1 | 2012 | 124 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1991 | 61 | 0.020 |
Why?
|
| Amputation | 1 | 2011 | 11 | 0.020 |
Why?
|
| Safety Management | 1 | 2011 | 15 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 1991 | 3 | 0.020 |
Why?
|
| Intensive Care Units | 2 | 2003 | 106 | 0.020 |
Why?
|
| Sinusitis | 1 | 2011 | 14 | 0.020 |
Why?
|
| Drug Therapy | 1 | 1991 | 21 | 0.020 |
Why?
|
| Bias | 1 | 2011 | 111 | 0.020 |
Why?
|
| Glycated Hemoglobin A | 1 | 2012 | 233 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2011 | 77 | 0.020 |
Why?
|
| Inpatients | 1 | 2011 | 80 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 1990 | 10 | 0.020 |
Why?
|
| Penicillins | 1 | 1990 | 7 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 111 | 0.020 |
Why?
|
| Insulin | 1 | 2011 | 208 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 624 | 0.020 |
Why?
|
| Technology | 1 | 1989 | 7 | 0.020 |
Why?
|
| San Francisco | 1 | 1989 | 68 | 0.020 |
Why?
|
| Schools, Medical | 1 | 1989 | 17 | 0.020 |
Why?
|
| Paralysis | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cranial Nerve Diseases | 1 | 2009 | 2 | 0.020 |
Why?
|
| Encephalitis | 1 | 2009 | 6 | 0.020 |
Why?
|
| Bacitracin | 1 | 1988 | 1 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1988 | 8 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 65 | 0.020 |
Why?
|
| Carrier State | 1 | 1988 | 8 | 0.020 |
Why?
|
| Urography | 1 | 1988 | 2 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 1988 | 2 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2008 | 32 | 0.020 |
Why?
|
| Research | 1 | 2008 | 73 | 0.020 |
Why?
|
| Kidney | 1 | 1988 | 54 | 0.020 |
Why?
|
| Warfarin | 1 | 2008 | 73 | 0.020 |
Why?
|
| Community Health Services | 1 | 2008 | 86 | 0.020 |
Why?
|
| Ethylmercury Compounds | 1 | 2007 | 2 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2007 | 3 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2007 | 28 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 38 | 0.020 |
Why?
|
| Health Care Coalitions | 1 | 2007 | 6 | 0.020 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2007 | 1 | 0.020 |
Why?
|
| Medical Audit | 1 | 2007 | 41 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1986 | 8 | 0.020 |
Why?
|
| Federal Government | 1 | 2006 | 14 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1986 | 35 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2007 | 115 | 0.020 |
Why?
|
| Heart Arrest | 1 | 1986 | 32 | 0.020 |
Why?
|
| Decision Theory | 1 | 2005 | 1 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2007 | 159 | 0.020 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2005 | 7 | 0.020 |
Why?
|
| Delivery, Obstetric | 1 | 2005 | 16 | 0.020 |
Why?
|
| Sociology | 1 | 2004 | 3 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 855 | 0.010 |
Why?
|
| Phototherapy | 1 | 2004 | 22 | 0.010 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2004 | 99 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 45 | 0.010 |
Why?
|
| Bioterrorism | 1 | 2003 | 5 | 0.010 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2003 | 6 | 0.010 |
Why?
|
| Milk, Human | 1 | 2003 | 7 | 0.010 |
Why?
|
| Smoking | 1 | 1986 | 494 | 0.010 |
Why?
|
| Maternal Health Services | 1 | 2003 | 12 | 0.010 |
Why?
|
| American Speech-Language-Hearing Association | 1 | 2002 | 1 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2002 | 79 | 0.010 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2001 | 4 | 0.010 |
Why?
|
| Salmeterol Xinafoate | 1 | 2001 | 2 | 0.010 |
Why?
|
| Organizations, Nonprofit | 1 | 2001 | 11 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 2000 | 16 | 0.010 |
Why?
|
| Disabled Children | 1 | 2000 | 29 | 0.010 |
Why?
|
| HIV Infections | 1 | 2006 | 695 | 0.010 |
Why?
|
| Obstetric Labor, Premature | 1 | 1999 | 10 | 0.010 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 1999 | 11 | 0.010 |
Why?
|
| Contraindications | 1 | 1998 | 15 | 0.010 |
Why?
|
| Comorbidity | 1 | 2000 | 619 | 0.010 |
Why?
|
| Death, Sudden | 1 | 1986 | 1 | 0.000 |
Why?
|